PolyPeptide Shortlists EQT and IDG Capital as Bidding Process Advances

Why It Matters

The selection of EQT and IDG signals strong private‑equity appetite for European biotech assets, and a deal could unlock value for PolyPeptide’s shareholders while accelerating consolidation in the Swiss pharma manufacturing sector.

Key Takeaways

• EQT AB and IDG Capital advance in PolyPeptide bidding.
• Altaris remains active but not yet shortlisted.
• PolyPeptide valued at ~$1.6 bn, still below historic highs.
• Deal would boost Swiss healthcare private‑equity activity.

Pulse Analysis

Founded in 1993, PolyPeptide Group has built a niche in peptide‑based therapeutics, supplying contract manufacturing for metabolic, oncologic, cardiovascular and neurological drugs. With facilities spanning Europe, the United States and India, the company serves a global roster of pharmaceutical clients and benefits from a diversified pipeline that de‑risked its revenue streams. The recent rally in its share price lifted the market capitalization to about $1.6 billion, yet the stock remains below levels seen before 2020, making it an attractive target for investors seeking upside in a stable, cash‑generating biotech platform.

The bidding round now features EQT AB, a Swedish private‑equity firm with a track record of healthcare carve‑outs, and IDG Capital, a China‑origin investor that has expanded into life‑science assets worldwide. Altaris, a U.S. specialist in pharma acquisitions, continues to conduct due diligence but has not secured a shortlist slot. Their interest reflects a broader surge in private‑equity activity across Swiss biotech, highlighted by Lone Star Funds’ purchase of a Lonza unit and SK Capital’s stake in Swixx Biopharma. Such momentum underscores Europe’s growing appeal as a hub for contract manufacturing expertise.

If a deal closes, PolyPeptide’s owners, led by billionaire Frederik Paulsen, could realize a premium over current market prices, while the buyer would gain immediate scale in peptide production and a platform for further roll‑ups. The transaction would also reinforce the trend of consolidating fragmented contract manufacturing services under larger private‑equity umbrellas, potentially driving operational efficiencies and cross‑selling opportunities. For the broader market, the outcome may set a pricing benchmark for similar biotech assets and stimulate additional capital inflows into the sector.